Objective-Previous studies have demonstrated a role for plasmin in regulating plasma von Willebrand factor (VWF) multimer composition. Moreover, emerging data have shown that plasmin-induced cleavage of VWF is of particular importance in specific pathological states. Interestingly, plasmin has been successfully used as an alternative to ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif) in a mouse model of thrombotic thrombocytopenic purpura. Consequently, elucidating the molecular mechanisms through which plasmin binds and cleaves VWF is not only of basic scientific interest but also of direct clinical importance. Our aim was to investigate factors that modulate the susceptibility of human VWF to proteolysis by plasmin. Approach and Results-We have adapted the VWF vortex proteolysis assay to allow for time-dependent shear exposure studies. We show that globular VWF is resistant to plasmin cleavage under static conditions, but is readily cleaved by plasmin under shear. Although both plasmin and ADAMTS13 cleave VWF in a shear-dependent manner, plasmin does not cleave at the Tyr1605-Met1606 ADAMTS13 proteolytic site in the A2 domain. Rather under shear stress conditions, or in the presence of denaturants, such as urea or ristocetin, plasmin cleaves the K1491-R1492 peptide bond within the VWF A1-A2 linker region. Finally, we demonstrate that VWF susceptibility to plasmin proteolysis at K1491-R1492 is modulated by local N-linked glycan expression within A1A2A3, and specifically inhibited by heparin binding to the A1 domain. Conclusions-Improved understanding of the plasmin-VWF interaction offers exciting opportunities to develop novel adjunctive therapies for the treatment of refractory thrombotic thrombocytopenic purpura. ADAMTS13 deficiency and circulating UL-VWF multimers can be observed in patients with inherited ADAMTS13 deficiency during the periods of clinical remission. 14, 18 Finally, complete deficiency of ADAMTS13 in transgenic mice models was not of itself sufficient to cause a TTP phenotype. 19, 20 Collectively, these findings suggest that the loss of ADAMTS13 may be necessary but not sufficient to induce clinical TTP, and support the hypothesis that additional factors beyond ADAMTS13 may contribute to TTP pathogenesis in vivo. 14, 21 Interestingly, Tersteeg et al 22 recently showed that significant activation of plasminogen to plasmin constitutes a common feature in patients during acute episodes of TTP. This observation is important because plasmin has previously been shown to proteolyze ADAMTS13. 23 However, in vitro and in vivo studies have confirmed that plasmin can also successfully degrade UL-VWF platelet aggregates. 22, 24 On the basis of these data, a possible role for plasmin as a novel therapy for patients with refractory TTP was proposed. 22 In addition, Herbig and Diamond 25 have further demonstrated that abnormal VWF fibers formed under pathological flow conditions are resistant to ADAMTS13 proteolysis, but remain susceptible to cleavage by plasmin. All together, these emerging data suggest that plasmin-induced cleavage of VWF may be of both physiological and pharmacological significance. Critically, however, the molecular mechanisms underlying VWF proteolysis by plasmin remain poorly understood.
V
on Willebrand factor (VWF) is a large plasma sialoglycoprotein that plays a critical role in primary hemostasis by mediating platelet adherence to exposed subendothelial collagen at sites of vascular injury. 1 In addition, VWF also acts as a carrier for procoagulant FVIII, protecting it against premature proteolytic degradation and clearance. 2 VWF is synthesized in endothelial cells and megakaryocytes initially as a monomer composed of a series of repeating domains (D′-D3-A1-A2-A3-D4-C1-C2-C3-C4-C5-C6-CK). 3 VWF monomers are assembled into dimers through the formation of C-terminal disulfide bonds in the endoplasmic reticulum. 4 Subsequently in the Golgi, a further round of N-terminal disulfide bond formation converts VWF dimers into longer multimeric structures. 5, 6 Multimeric forms of up to 100-or 200-mers may be present in the circulation. 7 Multimeric composition is a critical determinant of VWF functional activity as high molecular weight (HMW) VWF multimers bind to both collagen and platelets with significantly increased affinities and are thus more efficient in inducing platelet aggregation. 1, 8 In normal plasma, pathological accumulation of HMW VWF multimers is prevented by proteolysis of multimers with the plasma metalloprotease, ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type-1 repeats), which cleaves a single peptide bond (Tyr1605-Met1606) within the A2 domain of VWF. 9, 10 Inherited or acquired ADAMTS13 deficiency results in the accumulation of ultralarge VWF (UL-VWF) multimers in plasma. 11, 12 These UL-VWF can trigger the formation of pathological platelet aggregates, which obstruct the microvasculature, thereby causing thrombotic thrombocytopenia purpura (TTP). 13, 14 Congenital TTP has been associated with a series of different ADAMTS13 gene mutations. 11, 15 Interestingly, although inherited TTP often presents during infancy, significant variability in both age of onset and disease severity have been reported. 16, 17 Furthermore, ADAMTS13 deficiency and circulating UL-VWF multimers can be observed in patients with inherited ADAMTS13 deficiency during the periods of clinical remission. 14, 18 Finally, complete deficiency of ADAMTS13 in transgenic mice models was not of itself sufficient to cause a TTP phenotype. 19, 20 Collectively, these findings suggest that the loss of ADAMTS13 may be necessary but not sufficient to induce clinical TTP, and support the hypothesis that additional factors beyond ADAMTS13 may contribute to TTP pathogenesis in vivo. 14, 21 Interestingly, Tersteeg et al 22 recently showed that significant activation of plasminogen to plasmin constitutes a common feature in patients during acute episodes of TTP. This observation is important because plasmin has previously been shown to proteolyze ADAMTS13. 23 However, in vitro and in vivo studies have confirmed that plasmin can also successfully degrade UL-VWF platelet aggregates. 22, 24 On the basis of these data, a possible role for plasmin as a novel therapy for patients with refractory TTP was proposed. 22 In addition, Herbig and Diamond 25 have further demonstrated that abnormal VWF fibers formed under pathological flow conditions are resistant to ADAMTS13 proteolysis, but remain susceptible to cleavage by plasmin. All together, these emerging data suggest that plasmin-induced cleavage of VWF may be of both physiological and pharmacological significance. Critically, however, the molecular mechanisms underlying VWF proteolysis by plasmin remain poorly understood.
Previous studies have demonstrated that shear may enhance proteolysis of VWF by plasmin, as well as several other plasma proteases. 22, 24 In this study, we directly compared VWF proteolysis under static or shear conditions in the same assay and demonstrate that plasmin-mediated proteolysis of VWF is shear dependent. In addition, plasmin-mediated proteolysis of recombinant VWF truncated proteins was performed to localize a critical plasmin cleavage site to K1491-R1492 within the linker region between the A1 and A2 domains of VWF. Finally, we demonstrate that VWF susceptibility to plasmin proteolysis at K1491-R1492 is modulated by local N-linked glycan expression within A1A2A3 and is specifically inhibited by heparin binding to the A1 domain.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

pd-VWF Is Cleaved by Plasmin in a Shear-Dependent Manner
Recent studies have suggested that shear may influence the susceptibility of VWF to proteolysis by plasmin. 22, 24 To investigate this hypothesis, we adapted the vortex-ADAMTS13 cleavage assay as previously described by the Long Zheng laboratory. 26, 27 After incubation of pd-VWF with purified plasmin under static conditions for 5 minutes, no significant VWF proteolysis was observed ( Figure 1A ; Figure I in the online-only Data Supplement). In contrast, however, in the presence of vortex shear, a significant and time-dependent reduction in HMW multimers was apparent (0 minutes versus 5 minutes; P=0.005; Figure 1A and 1B; Figure I in the onlineonly Data Supplement). Moreover, a corresponding increase in low molecular weight multimers was also observed (0 minutes versus 5 minutes; P<0.0001). As the VWF preparation used was plasma-derived, and other plasma proteases can cleave VWF, 28, 29 the vortex VWF proteolysis experiment was repeated in the absence of added plasmin. In the absence of plasmin, no significant reduction in HMW was observed despite 5 minutes vortex (0 minutes versus 5 minutes, P=0.64; Figure 1B ). Furthermore, shear-related cleavage of VWF in this vortex assay was completely ablated in the presence of the known plasmin inhibitors aprotinin (0.5 μmol/L; P<0.0001) or ε-aminocaproic acid (50 mmol/L; P=0.006), respectively ( Figure 1C ). To determine whether the shear-induced ADAMTS13 cleavage site within the A2 domain of VWF is also cleaved by plasmin, immunoblotting was performed after vortexing using an antibody that specifically recognizes the ADAMTS13 140kDa N-terminal A2-cleavage product. 30 Following pd-VWF exposure to ADAMTS13 under shear, we observed a progressive increase in this cleavage product ( Figure 1D ). In contrast, however, in the presence of plasmin, no such cleavage band was seen despite the progressive loss in HMW multimers ( Figure 1D ). All together, these findings demonstrate that plasmin cleaves VWF in a shear-dependent manner. Moreover, although ADAMTS13 also cleaves VWF in a shear-dependent fashion, the plasmin-cleavage site(s) in VWF is distinct to that of ADAMTS13.
VWF Conformation Modulates Susceptibility to Plasmin Proteolysis
To further investigate how VWF conformation influences susceptibility to plasmin proteolysis, we studied VWF cleavage in the presence of the denaturant urea. Under static conditions, full-length VWF proteolysis by plasmin was significantly enhanced in the presence of increasing concentrations of urea (low molecular weight VWF after 120 minutes: 0 versus 1.5 mol/L urea P=0.027; Figure 2A ). Ristocetin binding to the A1 domain causes a conformational change that enhances VWF binding to platelet glycoprotein Ibα. 31 Moreover, ristocetin binding also significantly enhances VWF proteolysis by ADAMTS13. 31 Similarly, we observed that plasmin-induced VWF proteolysis was also significantly increased in the presence of ristocetin (low molecular weight VWF after 120 minutes: 0 versus 1.5 mg/mL ristocetin P=0.006; Figure 2B ; Figure II in the online-only Data Supplement). Previous studies have demonstrated that globular VWF is resistant to ADAMTS13 cleavage. 32 Similarly, our findings demonstrate that multimeric VWF is also resistant to plasmin proteolysis unless exposed to shear stress or in the presence of unfolding agents. Figure 1 . Human von Willebrand factor (VWF) is cleaved by plasmin in a shear-dependent manner. A, Purified human VWF (6 μg/mL) was incubated with plasmin (7.7 nmol/L) in the presence or absence of shear (vortexed at 2500 rpm). Samples are collected at 0, 1, 2, 3, and 5 minutes into tubes containing 15 μmol/L aprotinin. VWF proteolysis at each time point was analyzed by sodium dodecyl sulfate-agarose gel electrophoresis, immunoblotting, and densitometry as described in Materials and Methods section of this article. The area examined for densitometric analysis of high molecular weight (HMW) and low molecular weight (LWM) VWF is illustrated here and is applicable to all subsequent experiments. All experiments were performed in triplicate, and results described represent the means±SEM (**P<0.001 and ***P<0.0001 in comparison to control; ns, not significant). B, Purified pd-VWF was subjected to vortex-induced shear as before, in the presence or absence of added purified human plasmin (7.7 nmol/L). Samples were collected into aprotinin, and proteolysis assessed as above. C, Proteolysis of pd-VWF by plasmin under shear was repeated in the presence or absence of either aprotinin (0.5 μmol/L) or ε-aminocaproic acid (50 mmol/L) D, To investigate whether plasmin and ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif) cleave VWF at the same site, pd-VWF was vortexed at 2500 rpm in the presence of either recombinant (Continued )
Plasmin Cleaves VWF Within the A1-A2 Domains
Given the marked effect of ristocetin in enhancing VWF proteolysis by plasmin, we hypothesized that plasmin may cleave within the A1-A2-A3 domain region. To address this hypothesis, we examined plasmin-mediated proteolysis of recombinant VWF A domain truncated fragments ( Figure 3A) . In contrast to full-length VWF, recombinant A1A2A3-VWF was proteolyzed by plasmin under static conditions in the absence of any denaturants ( Figure 3B ). Moreover, this plasmin-mediated cleavage of A1A2A3-VWF was further enhanced in the presence of ristocetin ( Figure 3C ). Furthermore, although we observed plasmin-induced proteolysis of A1A2-VWF over time ( Figure 3D ), no significant cleavage of A2A3-VWF was seen ( Figure 3D ). Cumulatively, these data confirm a critical role for the A1 domain (aa1239-1494) in regulating VWF proteolysis by plasmin.
Plasmin Cleaves A1A2-VWF at K1491-R1492
As the A1A2 cleaved product is His-tagged at the C terminus, N-terminal sequencing of this product was performed to identify the site of proteolytic cleavage. RNSMV (Arg-AsnSer-Met-Val) were identified as the first five amino acids of the cleavage fragment. This sequence is only present in one location in human VWF, in the linker region between the A1 and A2 domains ( 1492 RNSMV 1496 ) ( Figure 4A ), and therefore suggests that plasmin cleaves between K1491 and R1492. Interestingly, both of these residues are highly conserved ( Figure 4A ). To confirm this putative plasmin cleavage site, K1491 was mutated to alanine in A1A2-VWF. In contrast to the plasmin-mediated proteolysis of wild-type (WT) A1A2, no proteolysis of A1A2-K1491A was observed over time ( Figure 4B ). Similarly, although WT D′D3A1A2A3-VWF was susceptible to plasmin cleavage, D'D3A1A2A3-K1491A/ R1492A was resistant to plasmin proteolysis ( Figure 4C ). Collectively, these findings demonstrate that plasmin cleaves VWF at the K1491-R1492 bond in the linker region between the A1 and A2 domains in this shear-sensitive region of VWF.
Heparin Inhibits Plasmin Cleavage of VWF
Several VWF-binding partners significantly enhance VWF susceptibility to ADAMTS13 proteolysis, including FVIII, 33 platelet glycoprotein Ibα, 34 ristocetin, 35 and heparin. 34 Both FVIII and glycoprotein Ibα are proteolyzed by plasmin. 36, 37 Consequently, we further investigated whether heparin binding might also promote plasmin proteolysis of full-length VWF. Interestingly, in contrast to the effect of heparin in enhancing VWF proteolysis by ADAMTS13, we observed a significant and concentration-dependent inhibition of plasmin-mediated proteolysis of pd-VWF under shear by heparin ( Figure 5A) . Similarly, proteolysis of the truncated A1A2-VWF fragment by plasmin under static conditions was also inhibited by heparin ( Figure 5B ). Tersteeg et al 22 previously postulated that the lysine-rich 1405 KKKK 1408 region in the A1 domain may be important in modulating plasminogen interaction with VWF. Interestingly, previous studies have also reported a heparinbinding role for this region. 38 To elucidate the mechanism underlying the inhibitory effect of heparin on plasmin-mediated VWF proteolysis, we investigated plasminogen binding to A1A2-VWF in the presence of heparin using the same assay as described by Tersteeg et al 22 In keeping with previous studies, immobilized recombinant A1A2-VWF bound to plasminogen in a saturable and concentration-dependent manner ( Figure 5C ). Moreover, this binding was inhibited by the soluble lysine analog ε-aminocaproic acid (data not shown). In the presence of heparin, binding of WT A1A2-VWF to plasminogen was markedly attenuated ( Figure 5C ). All together, these findings are consistent with the hypothesis that the lysine-rich 1405 KKKK 1408 region in the A1 domain of VWF plays critical roles in modulating interaction with both heparin and plasmin. Importantly, we further observed that binding of the A1A2-K1491A VWF variant to plasminogen was similar to that of WT A1A2-VWF, despite the loss of the plasmin cleavage site ( Figure 5D ). This observation confirms that the plasmin(ogen) binding and proteolytic sites on VWF are distinct.
Plasmin Cleaves VWF in a Glycan-Dependent but ABO-Independent Manner
Previous studies from our laboratory and others have demonstrated that VWF glycan determinants play a major role in modulating susceptibility to ADAMTS13 proteolysis. 35, 39, 40 Given the role of N-linked glycans in modulating A2 domain conformation, 41 we hypothesized that local N-linked glycans within A1A2A3 might also be important in modulating VWF proteolysis by plasmin. Only two N-linked glycans are expressed on A1A2A3-VWF at N1515 and N1574, respectively, within the A2 domain. Specific removal of these 2 N-linked glycans from A1A2A3-VWF by PNGase F digestion resulted in significantly increased susceptibility to plasmin proteolysis (4 hours; WT versus PNGase-treated, P=0.013; Figure 6A ).
ABO(H) blood determinants expressed on both the Nand O-linked glycans of human pd-VWF have been shown to modulate the susceptibility of pd-VWF to ADAMTS13 cleavage. 35, 42 As ABO(H) determinants are not expressed on recombinant VWF, 43, 44 we used blood group-specific pd-VWF to investigate whether ABO also influences plasmin-mediated proteolysis of VWF. Despite the significant effect of ABO blood group in regulating VWF proteolysis by ADAMTS13, no significant difference in plasmin-mediated proteolysis was observed for group AB VWF compared with group O Figure 3 . Plasmin cleaves within the A1-A2 domains of human von Willebrand factor (VWF). A, To investigate site(s) of plasminmediated proteolysis within VWF, a series of truncated VWF domain fragments were expressed and purified from HEK293T cells. B, Recombinant human A1A2A3-VWF was incubated with plasmin for up to 4 hours under static conditions. Samples were removed at specified time points for proteolysis analysis by immunoblotting as before. C, Recombinant A1A2A3-VWF was incubated with plasmin under static conditions in the absence or presence of ristocetin (1 mg/mL), and proteolysis analyzed on 4% to 12% Bis Tris acrylamide gels with immunoblotting. D, Recombinant human A1A2-VWF or A2A3-VWF were incubated with plasmin (12.8 nmol/L) for up to 1 hour. Samples were removed at each time point for analysis on 4% to 12% Bis Tris acrylamide gels with immunoblotting with anti-His horseradish peroxidase. WT indicates wild type. Figure 6C ). Nevertheless, taken together, these data demonstrate that Nand O-glycans expressed within the A1A2A3 domains of VWF play important roles in modulating proteolysis by both plasmin and ADAMTS13.
VWF (HMW 5 minutes AB versus O, P=0.1979;
Discussion
VWF multimer composition is a critical determinant of its hemostatic function. 1 The biological importance of regulating plasma VWF multimer distribution is illustrated by the fact that pathological accumulation of abnormal UL-VWF multimers is associated with thrombotic microangiopathy in TTP. 45, 46 Conversely, in patients with type 2A von Willebrand disease, increased proteolysis results in loss of normal HMW VWF multimers, and confers a significant bleeding phenotype. 47 Under steady-state conditions, VWF multimer distribution in normal plasma is primarily regulated by ADAMTS13-mediated proteolysis. Nevertheless, other proteases can also cleave multimeric VWF in vitro. 21 Moreover, accumulating recent evidence suggests that these proteases may have roles in regulating VWF multimer composition in vivo under specific conditions. 22, [48] [49] [50] [51] [52] For example, in a murine model of TTP, plasmin could regulate VWF multimer distribution in the absence of ADAMTS13. 22 Several other pathological conditions have also been associated with significant reductions in plasma ADAMTS13 levels, including acute The amino acid sequences of VWF protein from several species (human, feline, bovine, canine, murine, and porcine) were aligned using the T-Coffee multiple sequence alignment program. B, VWF A1A2 or A1A2 K1491A (10 μg/mL) were incubated with plasmin for up to 1 hour. Samples were removed at each time point and proteolysis analyzed by immunoblotting with anti-VWF horseradish peroxidase (HRP) or anti-His HRP. C, VWF D′A3 or D′A3 K1491A/R1492A (10 μg/mL) were incubated with plasmin for up to 4 hours. Samples were removed at each time point for analysis on 4% to 12% Bis Tris acrylamide gels with immunoblotting with anti-VWF HRP or anti-His HRP.
Figure 5. Heparin inhibits plasmin cleavage of von Willebrand factor (VWF).
A, Full-length pd-VWF was vortexed at 2500 rpm in the absence or presence of plasmin or heparin (0.3-30 mg/mL). Samples are removed at 0 and 5 minutes for analysis on 1.8% sodium dodecyl sulfate-agarose gels with immunoblotting and densitometry. B, Recombinant A1A2-VWF (10 μg/mL) was incubated with plasmin in the presence of heparin (0-300 μg/mL) for 1 hour. Samples were removed at 1 hour for proteolysis analysis. C, Plate-binding of plasminogen (25-200 μg/mL) to immobilized recombinant human wild-type (WT) A1A2-VWF was detected by anti-plasminogen horseradish peroxidase (HRP). Binding experiments were repeated in the presence or absence of added heparin (0-300µg/mL). D, Binding of plasminogen (25-200μg/mL) to immobilized A1A2-K1491A (5 μg/mL) was detected by anti-plasminogen HRP as before.
liver injury, 48 cerebral malaria, 53 sickle cell disease, 54 and Dengue. 51 Importantly, however, despite low or even undetectable ADAMTS13 activity levels, UL-VWF multimers are not observed in many individuals with these conditions. 49 The absence of UL-VWF in these different patient cohorts is likely to be attributable to different molecular mechanisms, including consumption in platelet-rich microthrombi. Nevertheless, recent reports 21, 22, [48] [49] [50] [51] [52] have also postulated that VWF proteolysis through ADAMTS-13 independent pathways may be important in this context.
In the normal circulation, VWF adopts a globular conformation. 55 Shear stress triggers unwinding of globular VWF and conformational changes within the A domains, 32 exposing the glycoprotein Ibα-binding site in the A1 domain and the ADAMTS13 cleavage site in the A2 domain. 56, 57 In this study, we directly compare plasmin-mediated proteolysis of VWF under both static and shear conditions in a controlled environment and show that human pd-VWF is relatively resistant to proteolysis by 7.7 nmol/L plasmin under static conditions. Previous studies reporting proteolysis of VWF by plasmin under static conditions have used significantly higher plasmin concentrations. 24, 58 In contrast, however, our data show that HMW VWF is rapidly cleaved by 7.7 nmol/L plasmin under exposure to shear stress, which would parallel conditions present in stenosed arteries in vivo. Local plasmin concentrations of ≈10 nmol/L at sites of vascular injury, and >100 nmol/L after systemic thrombolytic therapy, have been estimated. 24, 59 Although both plasmin and ADAMTS13 cleave VWF in a shear-dependent manner, our findings demonstrate that plasmin does not cleave VWF at the ADAMTS13 site (Tyr 1605-Met 1606 in A2).
Using a series of recombinant VWF truncated proteins, we have localized a plasmin cleavage site in VWF. Plasmin specifically cleaves VWF at the K1491-R1492 peptide bond that is located in the A1-A2 linker region. The lysine-rich 1405 
KKKK
1408 region in the VWF A1 domain was recently postulated to play a role in mediating interaction with plasmin. 22 Moreover, this region is important in modulating heparin binding to VWF. 38 Heparin has been reported to significantly enhance VWF proteolysis by ADAMTS13. 34 In contrast, our novel data demonstrate that heparin binding to the A1 domain of VWF attenuates plasmin-mediated VWF proteolysis in a dosedependent manner. In binding studies, we confirmed that plasminogen binding to A1A2-VWF was significantly reduced in Figure 6 . Plasmin cleaves von Willebrand factor (VWF) in a glycan-dependent but ABO-independent manner. A, N-linked glycans were removed from A1A2A3-VWF by digestion with PNGase F. Wild-type and PNGase F-treated A1A2A3-VWF (10 μg/mL) were then incubated with plasmin for up to 4 hours. Samples were removed at each time point for analysis on 4% to 12% Bis Tris acrylamide gels with immunoblotting. Samples were removed into aprotinin at each time point for analysis on 4% to 12% Bis Tris acrylamide gels with immunoblotting. B, Human pd-VWF was purified from pooled blood group AB or blood group O normal donors. The AB-and O-VWF preparations were then vortexed at 2500 rpm in the absence or presence of plasmin (7.7 nmol/L). Samples were removed at 0, 1, 3, and 5 minutes for analysis on 1.8% sodium dodecyl sulfate-agarose gels with immunoblotting. The loss of high molecular weight multimers over time was determined by densitometry.
the presence of heparin. Importantly, however, we observed that, despite site-directed mutagenesis of the plasmin cleavage site, A1A2-K1491A VWF binding to plasminogen was not reduced indicating that the plasmin(ogen)-binding site and the plasmin proteolysis sites within VWF are distinct. Therefore, our data show that under shear stress conditions, conformational changes in A1A2 facilitate plasmin binding to lysine-rich regions in the VWF A1 domain, and subsequently enable specific plasmin cleavage at the K1491-R1492 peptide bond within the VWF A1-A2 linker region. This pattern of distinct binding and cleavage sites as well as shear-enhanced and conformation-dependent cleavage has clear similarities to the VWF-ADAMTS13 interaction. 32, 60 To date, no VWF gene mutations involving the K1491-R1492 plasmin cleavage site have been described. However, both type 2A and type 2B von Willebrand disease are characterized by the loss of HMW multimers due, in part, to enhanced proteolysis. 61, 62 On the basis of our data on the critical role of A1A2 conformation in regulating susceptibility to plasmin proteolysis, it seems likely that some type 2A and 2B mutations may lead to enhanced proteolysis by plasmin and ADAMTS13. Furthermore, given the importance of shear in regulating plasmin-mediated VWF proteolysis, it is plausible that plasmin cleavage may contribute to the loss of HMW multimers observed in patients in whom pathological local shear stress levels are generated (eg,) acquired von Willebrand disease secondary to aortic stenosis or left ventricular assist devices (LVADs). 63, 64 Finally, plasmin-mediated VWF proteolysis after administration of thrombolytic treatment has been described in patients with myocardial infarction 65 and deep vein thrombosis, 61 and thus may be a contributing factor in the clinical bleeding risk associated with systemic thrombolysis.
In previous studies, we and others have shown an important role for VWF glycans in modulating VWF cleavage by ADAMTS13 39, 40, 42, 66, 67 and by plasmin. 29 Similarly, our novel findings demonstrate that VWF glycans also determine susceptibility to plasmin proteolysis, but in addition identify some important differences in the effects of VWF glycans in regulating proteolysis by plasmin compared with ADAMTS13. First, although the loss of terminal α2 to 6 linked sialic acid from human VWF significantly inhibits ADAMTS13 proteolysis, 66 desialylation actually enhances proteolysis by plasmin. 68 Second, N-linked glycans expressed at N1515 and N1574 within the A2 domain protect VWF against proteolysis by both plasmin and ADAMTS13. 67, 69 Finally, ABO(H) blood group determinants modulate VWF susceptibility to proteolysis by ADAMTS13 (O≥B>A≥AB) 35 but do not influence plasmin-mediated cleavage. We hypothesize that VWF glycan determinants modulate interactions with both plasmin and ADAMTS13 by modifying protein conformation. Consequently, removal of specific glycans in the A1A2A3 domains result in conformations that are more permissive for either plasmin or ADAMTS13 cleavage. Further studies are necessary to define the molecular mechanism(s) through which glycans within the A domains of VWF regulate plasmin-mediated proteolysis. Nevertheless, these findings are of clinical relevance in that significant quantitative and qualitative variations in VWF glycan expression have been previously been reported in both the normal population 70, 71 and in patients with different disease states. 72, 73 In conclusion, accumulating recent data have demonstrated that in addition to ADAMTS13, plasmin may also play an important role in regulating plasma VWF multimer distribution, particularly under specific pathological conditions that present with the accumulation of HMW VWF multimers. 22, 48, 50, 51, 54 Consequently, elucidating the molecular mechanisms through which plasmin binds and cleaves multimeric VWF is not only of basic scientific interest but also of direct translational importance. Improved understanding of the plasmin-VWF interaction may offer exciting opportunities to develop novel adjunctive therapies for the treatment of refractory TTP, which continues to be associated with significant morbidity and mortality. In addition, using thrombolytic therapy to lyse VWFdependent platelet aggregates in sites of high shear stress may also be useful, particularly in pathological conditions where UL-VWF is resistant to ADAMTS13 proteolysis. 25, 53 
